Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Pharmaceuticals has introduced an authorised generic version of Caduet in the US market under an agreement with Pfizer.
Subscribe to our email newsletter
Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate indicated for patients suffering from both, high blood pressure and high levels of cholesterol.
Ranbaxy Americas senior vice-president and regional director Venkat Krishnan said the launch of Atorvastatin-Amlodipine besylate tablets will further complement its goal to bring high quality, affordable generic medicines to the US healthcare system.
"The introduction of Atorvastatin-Amlodipine besylate tablets is a significant and important addition to our portfolio of cardio-vascular products, in the US,” Krishnan added.